The differential expression of diverse kinases including LYN, CRKL, EPHA6 and AXL between the high grade glioma cells derived from patients of different ages suggests a number of potential new drug targets, and provides impetus for molecular pathology investigations to confirm their presence in vivo. This evidence concerns the gene CRKL and central nervous system cancer.